A detailed history of Woodline Partners LP transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 1,783,202 shares of MORF stock, worth $102 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares
1,783,202
Previous 100,000 1683.2%
Holding current value
$102 Million
Previous $3.52 Million 1625.94%
% of portfolio
0.61%
Previous 0.03%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$26.12 - $34.07 $44 Million - $57.3 Million
1,683,202 Added 1683.2%
1,783,202 $60.8 Million
Q1 2024

May 15, 2024

BUY
$26.64 - $40.31 $2.66 Million - $4.03 Million
100,000 New
100,000 $3.52 Million
Q3 2023

Nov 14, 2023

BUY
$21.33 - $59.42 $15.6 Million - $43.4 Million
730,452 Added 147.74%
1,224,881 $28.1 Million
Q2 2023

Aug 14, 2023

BUY
$34.33 - $62.11 $4.96 Million - $8.97 Million
144,429 Added 41.27%
494,429 $28.3 Million
Q1 2023

May 15, 2023

SELL
$26.01 - $48.69 $7.51 Million - $14 Million
-288,552 Reduced 45.19%
350,000 $13.2 Million
Q4 2022

Feb 14, 2023

BUY
$24.14 - $30.37 $15.4 Million - $19.4 Million
638,552 New
638,552 $17.1 Million
Q4 2021

Feb 14, 2022

SELL
$43.27 - $65.72 $939,175 - $1.43 Million
-21,705 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$53.61 - $67.5 $2.03 Million - $2.56 Million
-37,951 Reduced 63.62%
21,705 $1.23 Million
Q2 2021

Aug 16, 2021

BUY
$45.13 - $64.99 $1.57 Million - $2.26 Million
34,747 Added 139.5%
59,656 $3.42 Million
Q1 2021

May 17, 2021

BUY
$29.77 - $84.85 $741,540 - $2.11 Million
24,909 New
24,909 $1.58 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.